clesrovimab
Trade name: Enflonsia
mAbapproved
Approved
Jun 9, 2025
Clinical trial activity
4 trials · 1 clinical orgs · 1 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Aug 31, 2018 (NCT03524118)
Timeline
Indications
Approved for
Mechanism of action
- Fusion glycoprotein F0INHIBITOR
Fusion glycoprotein F0 inhibitor
Site IV
- RSV F-proteinImmunity, passive
RSV F-protein immunity, passive
Approval history
- approvedPriority reviewJun 9, 2025
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297783 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04938830 | Phase 3 | Nov 30, 2021 | Merck |
| NCT04767373 | Phase 2/Phase 3 (Phase 3) | Apr 7, 2021 | Merck |
| NCT04086472 | Phase 2 | Oct 21, 2019 | Merck |
| NCT03524118 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2018 | Merck |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 4 | 4 | 2 | 2018 |
1 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Merck | For profit | MKTG | Jun 9, 2025 |